Join
Live feed
·
PRReleasevia Quantisnow
Acurx Pharmaceuticals Inc. logo

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

ByQuantisnow·Wall Street's wire, on your screen.
ACXP· Acurx Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACXP (Acurx Pharmaceuticals Inc.) and more on Quantisnow.

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection | Quantisnow